SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Recursion Presents Phase 2 REC-4881 Data in FAP

The company said the data showed deep, durable polyp burden reductions, with activity across the GI tract and in larger, higher-risk polyps.

RXRX

Related stories